✧ Top storyDaily Obesity Pill Orforglipron Cut Bodyweight Up to 8.7% in Japanese Phase 3 Trial
A phase 3 trial found an investigational daily pill outperformed placebo for weight loss in Japanese adults with obesity.
- 8.7% max weight loss
- 0.6% with placebo
- 72-week trial
Orforglipron isn't approved yet, so nothing here changes what's at the pharmacy today. But the pattern holds for approved GLP-1 medicines too: they work on appetite and fullness signals, not on the muscle loss or nutrient gaps that rapid weight loss can bring. I pair these medicines with a whole-food, high-protein diet, fiber from vegetables and legumes, and resistance training to protect muscle. Many people do well on a much lower dose of approved GLP-1 drugs, often 10 to 20% of the labeled dose, worked out with the prescribing doctor instead of adjusting on their own. Watch for nausea and vomiting, the most common reasons people stopped the drug here.
Source: The Lancet Diabetes & Endocrinology · Oct 30, 2026


























The Parasite PROBLEM
Build MUSCLE As You Age
Make Time for FAMILY
Healing the SOUL
The Healthcare System Is BROKEN
The SECRET to Longevity
What Cancer Taught Me


